Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3510 - Characterization of cachectic patients with non-small cell lung cancer (NSCLC) according to their modified Glasgow Prognostic Score (mGPS)


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  End-of-life Care;  Thoracic Malignancies


Barry Laird


Annals of Oncology (2017) 28 (suppl_5): v497-v501. 10.1093/annonc/mdx382


B. Laird1, D. McMillan2, S. Kaasa3, M. Fallon4, R. Skipworth5, D. Currow6, R. Giorgino7

Author affiliations

  • 1 Institute Of Genetics And Molecular Medicine, University of Edinburgh, EH4 2XR - Edinburgh/GB
  • 2 Academic Unit Of Surgery, New Lister Building, Glasgow Royal Infirmary, University of Glasgow, Glasgow/GB
  • 3 Department Of Oncology, Oslo University Hospital and University of Oslo, Oslo/NO
  • 4 Institute Of Genetics And Molecular Medicine, University of Edinburgh, Edinburgh/GB
  • 5 Clinical Surgery, University of Edinburgh, Edinburgh/GB
  • 6 Impacct – Improving Palliative Aged And Chronic Care Through Clinical Research And Translation, Faculty Of Health, University of Technology Sydney, 2007 - Sydney/AU
  • 7 Research And Development Innovation And Strategy Department, Helsinn Healthcare, Lugano/CH


Abstract 3510


Patients with advanced NSCLC often develop anorexia/cachexia, a comorbidity characterized by decreased body weight or low body mass index (BMI), which negatively impacts quality of life and life expectancy. Weight loss and BMI were suggested to have independent prognostic value (Martin L et al, JCO 2015). The mGPS (0–2) has independent prognostic value, where patients with mGPS 2 (C-reactive protein levels >10mg/L and albumin levels


Patients with unresectable stage III/IV NSCLC and cachexia (BMI


At baseline, 36% patients had mGPS 0 (n = 296), 49% mGPS 1 (n = 396) and 15% mGPS 2 (n = 123). Patients who lost 10% body weight, a higher percentage had mGPS 2. Patients with mGPS 2 had on average substantially lower values of body weight, body composition parameters, handgrip strength and anorexia/cachexia and fatigue scores than the other mGPS subgroups (Table).Table:


Baseline characteristics based on mGPS score
mGPS 0 (n = 296)mGPS 1 (n = 396)mGPS 2 (n = 123)
Body weight loss, n (%) ≤ 10% > 10%205 (43.0) 92 (27.1)218 (45.7) 178 (52.5)54 (11.3) 69 (20.4)
Mean body weight, kg (SD)66.9 (13.66)67.4 (12.73)63.0 (13.77)
Mean lean body mass, kg (SD)44.9 (8.64)46.2 (7.78)44.5 (8.54)
Mean appendicular lean body mass, kg (SD)19.3 (4.59)19.7 (3.95)18.4 (4.25)
Mean fat mass, kg (SD)19.4 (8.06)19.0 (7.80)16.3 (8.01)
Mean handgrip strength, kg (SD)32.2 (11.74)32.7 (10.92)27.2 (9.91)
Mean FAACT Anorexia/Cachexia subscale score (SD)31.6 (7.92)29.5 (8.16)25.5 (8.77)
Mean fatigue subscale score (SD)32.4 (9.74)30.6 (10.21)25.4 (10.95)

FAACT, Functional Assessment of Anorexia/Cachexia Therapy; mGPS, modified Glasgow prognostic score; SD, standard deviation.


While patients with cachexia present mGPS scores that vary from 0–2, a higher percentage of patients with mGPS 2 was observed among those with >10% body weight loss. The baseline characteristics observed in patients with mGPS 2 are worse than in the other mGPS subgroups, suggesting that mGPS may be helpful in identifying patients with more-advanced cachexia.

Clinical trial identification

ROMANA 1: NCT01387269 ROMANA 2: NCT01387282

Legal entity responsible for the study





B. Laird: Advisory board membership: Chugai Pharma. S. Kaasa: Stock ownership: Eir solutions AS. R. Skipworth: Corporate-sponsored research: Research grant/agreement with Novartis. D. Currow: Unpaid advisory board member for Helsinn. Paid consultant and receive payment for intellectual property with Mayne Pharma and am a consultant with Specialist Therapeutics Australia Pty. Ltd. R. Giorgino: Helsinn Healthcare employee. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.